Stoke Therapeutics (STOK) Return on Capital Employed (2019 - 2026)
Stoke Therapeutics (STOK) recorded quarterly Return on Capital Employed of 47.49% in Q1 2026, down 664.59% quarter-over-quarter from 6.21% in Q4 2025, and down 6048.0% on a YoY basis from 0.8% in Q1 2025.
Stoke Therapeutics (STOK) Return on Capital Employed (2019 - 2026) Analysis & Trends
Stoke Therapeutics' Return on Capital Employed history runs 8 years deep, the most recent figure standing at 47.49% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 6048.0% year-over-year to 47.49%; the TTM figure through Mar 2026 stood at 47.49% (down 6048.0% YoY), while the FY2025 annual figure was 7.17%, up 4113.0% from the prior year.
- Return on Capital Employed was 47.49% for Q1 2026 at Stoke Therapeutics, down from 6.21% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 12.98% in Q1 2025 to a low of 65.38% in Q1 2024.
- Historically, Return on Capital Employed has averaged 34.13% across 5 years, with a median of 43.91% in 2023.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed surged 7837 bps in 2025, then plunged 6048 bps in 2026.
- A 5-year view of Return on Capital Employed shows it stood at 44.32% in 2022, then fell by 27 bps to 56.46% in 2023, then gained by 26 bps to 41.82% in 2024, then soared by 85 bps to 6.21% in 2025, then tumbled by 665 bps to 47.49% in 2026.
- The last three Return on Capital Employed figures came in at 47.49% (Q1 2026), 6.21% (Q4 2025), and 8.22% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.95 Bn | - | -47.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -47.49% |
| Dec 31, 2025 | -6.21% |
| Sep 30, 2025 | 8.22% |
| Jun 30, 2025 | 11.28% |
| Mar 31, 2025 | 12.98% |
| Dec 31, 2024 | -41.82% |
| Sep 30, 2024 | -46.80% |
| Jun 30, 2024 | -54.03% |
| Mar 31, 2024 | -65.38% |
| Dec 31, 2023 | -56.46% |
| Sep 30, 2023 | -50.34% |
| Jun 30, 2023 | -45.36% |
| Mar 31, 2023 | -43.91% |
| Dec 31, 2022 | -44.32% |
| Sep 30, 2022 | -39.01% |
| Jun 30, 2022 | -34.60% |
| Mar 31, 2022 | -36.95% |
| Dec 31, 2021 | -37.55% |
| Sep 30, 2021 | -30.79% |
| Jun 30, 2021 | -25.49% |